Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
23andMe Allies With Genentech
by Marc S. Reisch
January 12, 2015
| A version of this story appeared in
Volume 93, Issue 2
Genentech has reached an agreement with 23andMe to generate whole-genome sequencing data from 3,000 volunteers with Parkinson’s disease. The two hope to discover new therapeutic targets for treating the nervous system disorder. 23andMe says it will also be able to share the genetic information generated through the project with other researchers. A year ago, FDA ordered 23andMe to stop selling its direct-to-consumer genome test kits without the agency’s approval.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X